The Japan diabetes market reached a value of US$ 4.34 Billion in 2019. Looking forward, IMARC Group expects the market to exhibit moderate growth during 2020-2025. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use industries. These insights are included in the report as a major market contributor.
Diabetes refers to a chronic disease in which the ability of a human body to produce and respond to insulin hormone becomes impaired. This results in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood. In Japan, a large section of the population is over 60 years, an age when type-2 diabetes becomes more prevalent. Moreover, as the Japanese diet consists of a significant portion of refined carbohydrates, like white rice and noodles, it puts the population at a higher risk of developing and aggravating diabetes.
Japan Diabetes Market Drivers:
With the growing influence of western cuisines, increasing working hours and declining domestic agricultural production, consumers are now relying on processed food products and fast-food like burger, taco, hotdog and pizza. As these food products are high in carbohydrates, sodium and preservatives, their rising consumption has increased the cases of diabetes in the country. The other factors that are contributing to the increasing cases of diabetes include growing obese population and sedentary lifestyles. However, to minimize the prevalence of diabetes in the country, the Government of Japan is undertaking several initiatives. For instance, it is offering health insurance to both the citizens and non-citizens residing for more than a year in Japan through their universal health care system.
Breakup by Segment:
Currently, insulin represents the dominant segment, accounting for the majority of the total market share. Insulin in Japan is usually taken through pens, pumps, syringes and jet injectors as they offer convenience to the patients. Increasing diagnostic rates and awareness among patients are enabling them to incorporate insulin therapy for treating diabetes.
The competitive landscape of the market has been analyzed in the report with detailed profiles of key players operative in the industry.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at